Skip to main content
OpenTrials
Completed

NCT Number: NCT03889236

Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.

Evaluate the effect of a fasting mimicking diet and a food supplement on the microvascular health and urinary heparanase levels in South Asian type 2 diabetic patients with albuminuria.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • South Asian patient with diabetes mellitus type 2.
  • Female or male, aged between 18 and 75 years.
  • Body Mass Index ≥18.5.
  • CKD-EPI >45 ml/min/1.73m² .
  • Proven microalbuminuria defined as albumin/creatinine ratio ≥0.3 and <30 mg/mmol (single portion) or 3-300 mg albumin per day (24 hours urine collection) in the last twelve months.
  • Systolic blood pressure ≤ 180 mmHg.
  • Treatment with hypoglycemic drugs: metformin, sulphonylureas and/or insulin.
  • Subject is willing to participate in the study, must be able to give informed consent and the consent must be obtained prior to any study procedure.
  • Patients must be able to adhere to the study visit schedule and protocol requirements.
  • If female and of child-bearing age, patients must be non-pregnant, non-breastfeeding, and use adequate contraception.

4.3 Exclusion

Exclusion criteria

  • Any concurrent illness, disability or clinically significant abnormality that may, as judged by the investigator, affect the interpretation of clinical efficacy or safety data or prevent the subject from safely completing the assessments required by the protocol.
  • Non-diabetic renal disease e.g. known polycystic kidney disease.
  • Use of LMW heparin and/or immunosuppressive drugs.
  • Significant food allergies for galactose, nuts, soy, tomato, corn, grape, melon and artichoke, which would make the subject unable to consume the food provided.
  • Signs of active infection or autoimmune disease, requiring systemic treatment.
  • A psychiatric, addictive or any disorder that compromises ability to give truly informed consent for participation in this study.
  • Malignancy (including lymphoproliferative disease) within the past 2-5 years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence).
  • Use of any other investigational drug.
  • Patient has enrolled another clinical trial within last 4 weeks.

Treatment and study plan

Fasting mimicking diet Prolon

Other

5-day fasting mimicking diet

Other names: FMD, Prolon, L-Nutra

Food supplement Endocalyx

Dietary Supplement

Food supplement

Other names: Endocalyx, Q-prime

Placebo

Dietary Supplement

Placebo

Primary outcomes

  1. Percentage change from baseline in the Microvascular Health Index in the fasting mimicking diet or food supplement group compared to the placebo group

    Time frame: 3 months

Secondary outcomes

  1. Percentage change from baseline in Urine albumin-to-creatinine ratio (UACR) in the fasting mimicking diet or food supplement group compared to the placebo

    Time frame: 3 months

  2. Percentage change from baseline in urinary heparanase levels in the fasting mimicking diet or food supplement group compared to the placebo

    Time frame: 3 months

  3. Percentage change from baseline in urinary MCP-1 levels in the fasting mimicking diet or food supplement group compared to the placebo

    Time frame: 3 months

  4. Percentage change from baseline in specific urinary heparan sulfate domains in the fasting mimicking diet or food supplement group compared to the placebo

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

Leiden University Medical Center

Other

Collaborators

  • Dutch Kidney Foundation
  • Health Holland
  • Radboud University Medical Center

Registry information

Official study title

The Effect of Dietary Interventions on Endothelial Glycocalyx Dimensions and Barrier Function in South Asian Patients With Diabetic Nephropathy.

Acronym: Glycotreat

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Mar 26, 2019
Registry last updated
Feb 18, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.